Newer antihypertensive drugs.
We review three new classes of antihypertensive drugs: imidazolines, monatepil, and neutral endopeptidase inhibitors. Imidazolines are a new generation of central acting drugs. Because of their greater affinity for imidazoline receptors rather than alpha 2-adrenoreceptors, they cause less fatigue and dry mouth than the older central acting drugs. Monatepil is a single drug with both calcium antagonist and peripheral alpha 1-antagonist properties. This agent not only lowers blood pressure but also lowers serum cholesterol, an effect mediated by its alpha-antagonism, and has anti-lipid peroxidation properties. Monatepil might become an effective antiatherosclerosis drug. Neutral endopeptidase inhibitors lower blood pressure by inhibiting the metabolism of atrial natriuretic peptide and other vasoactive peptides.
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003988:Dibenzothiepins / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008715:Methionine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010080:Oxazoles / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D000077769:Rilmenidine
D000959:Antihypertensive Agents; D003988:Dibenzothiepins; D007093:Imidazoles; D010080:Oxazoles; D010879:Piperazines; D011480:Protease Inhibitors; C069018:SCH 42495; D008715:Methionine; C043482:moxonidine; C067818:monatepil; D000077769:Rilmenidine